Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

BRIEF-Eli Lilly Announces Positive Top-Line Phase 3 Results For Taltz

2018-02-13 reuters
* LILLY ANNOUNCES POSITIVE TOP-LINE PHASE 3 RESULTS FOR TALTZ® (IXEKIZUMAB) IN ANKYLOSING SPONDYLITIS (RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS) (2-0)

BRIEF-Eli Lilly And Co Q4 Non-GAAP Earnings Per Share $1.14

2018-01-31 reuters
* ELI LILLY - RECORDED ESTIMATED CHARGE OF $1.9 BILLION IN QUARTER ASSOCIATED WITH U.S. TAX REFORM LEGISLATION, CHARGES ASSOCIATED WITH REDUCING COST STRUCTURE (2-0)

Radius Health to Get Third Day-180 List of Outstanding Issues

2017-12-18 zacks
Radius Health, Inc. (RDUS - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) will provide a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC. (130-1)

Intersect ENT (XENT) SINUVA Implant Receives FDA Approval

2017-12-13 zacks
Intersect ENT, Inc. (XENT - Free Report) received approval from the FDA for SINUVA Sinus Implant. The company has been focused on developing innovative therapies for chronic sinusitis patients. (66-0)

BRIEF-Lilly's Cyramza meets Primary Endpoint in gastric cancer study

2017-12-08 reuters
* LILLY REPORTS TOP-LINE RESULTS FROM CYRAMZA® (RAMUCIRUMAB) PHASE 3 STUDY IN FIRST-LINE ADVANCED GASTRIC CANCER (2-0)

New, long-acting drugs cut frequency of migraine headaches

2017-11-29 nzherald.co.nz
New, long-acting drugs may hold hope for millions of people who often suffer migraines. Studies of two of these medicines, given as shots every month or so, found they cut the frequency of the notoriously painful and disabling headaches. (37-0)

Pulling Iron From Brain May Offer Hope in Alzheimer’s Fight - Bloomberg

2017-11-29 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (52-0)

9 Must-Own Stocks That Have Paid Over a Century of Dividends

2017-11-29 kiplinger
Dividend stock investing is inherently a long-term enterprise. After all, companies only pay their investors dividends once a quarter and dividend yields are calculated on an annualized basis. If you own a stock for only a few months, you're not experiencing the full dividend potential. And if you only own a few weeks, there's a chance you don't get paid a dividend at all. (5-0)

HHS nominee Azar says drug pricing a top priority

2017-11-29 reuters
WASHINGTON (Reuters) - Alex Azar, the Republican nominee to head the U.S. Department of Health and Human Services and a former Eli Lilly & Co top executive, said on Wednesday that drug prices are too high and pledged to work on solutions despite his industry background. (2-0)

HHS nominee Azar says drug pricing a top priority

2017-11-29 channelnewsasia
Alex Azar, the Republican nominee to head the U.S. Department of Health and Human Services and a former Eli Lilly & Co top executive, said on Wednesday that drug prices are too high and pledged to work on solutions despite his industry background. (2-0)

The Investment Case For Ascendis Pharma

2017-11-29 seekingalpha
Ascendis' TransCon hGH has the potential to become the new standard of care in the growth hormone deficiency market. (35-2)

Hold On To Nektar Therapeutics: There Is Much More Ammunition Left In Its Partnered Research Programs

2017-11-29 seekingalpha
Nektar Therapeutics is a biopharmaceutical company which depends heavily on payments received from partners. The company has either collaborated with pharmaceutical players for developing novel drugs targeting multiple therapeutic areas or has out licensed its PEGylated polymer conjugation technology. The limited amount of direct product sales coupled with concoction of upfront payments, milestone payments, royalties, and licensing fees from leading companies such as Shire (SHPG), AstraZeneca (AZN), Bayer, Amgen (AMGN) and others makes it pretty difficult to predict revenue growth for the company on quarterly basis. (233-0)

Trump's Pick to Lead HHS to Face Senate Questions on Drug Prices - Bloomberg

2017-11-29 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (2-0)

Skeptical Democrats to quiz Trump health pick on drug prices

2017-11-29 nzherald.co.nz
WASHINGTON (AP) — Skeptical Democratic senators are getting a chance to question President Donald Trump's pick for health secretary about what he'll do about rising drug prices and the future of "Obamacare." (2-0)

Business Highlights

2017-11-28 nzherald.co.nz
WASHINGTON (AP) — A key Senate committee advanced a sweeping tax package to the full Senate on Tuesday, handing Republican leaders a victory as they try to pass the nation's first tax overhaul in 31 years. The Senate Budget Committee voted 12-11 to advance the bill as two committee Republicans who had said they were considering voting against the measure — Bob Corker of Tennessee and Ron Johnson of Wisconsin — backed the legislation. (6-0)